article thumbnail

Startups Weekly: VCs are drunk on beverage startups

TechCrunch LA

For one, because millennials, according to various studies, are consuming less alcohol than previous generations and are therefore seeking non-alcoholic beverage alternatives. From wellness chat and journaling apps to therapy substitutes to fitness companies, stick wellness in a pitch and investors will take a second look. Fundraising.

Startup 223
article thumbnail

Bio Roundup: Theranos Cuts, Alnylam Stops, Nobel Eats Its Own & More

Xconomy

—Alnylam Pharmaceuticals (NASDAQ: ALNY ) of Cambridge, MA, said that it would shelve its drug revusiran after 18 patients died in a Phase 3 study to treat the rare disease transthyretin amyloidosis. Territorial Acquisitions” by Joaquin Martinez via Creative Commons. She refused to discuss Edison at the time. —The U.S.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Phoenix Shops Its Cancer Drug as Potential Alzheimer’s Treatment

Xconomy

Over more than two decades, Perry has studied the possibility that diseases like Alzheimer’s may get their start because the body produces too many variants of oxygen, called free radicals, which cause cell damage, and not enough antioxidants to limit the damage.

Study 68
article thumbnail

Retrophin Drug Licensed by Shkreli Shows Positive Phase 2 Results

Xconomy

Retrophin , the drug developer founded by controversial former biotech executive Martin Shkreli, has posted positive results from a midstage study for its treatment for a rare kidney disease. The company plans to present detailed results at an upcoming medical meeting or in a peer-reviewed journal, it said in a statement.

article thumbnail

Bio Roundup: Precision Med and Google, Heron, Lilly, Sarepta & More

Xconomy

Celgene paid Acetylon $100 million in 2013 for an option to buy the company outright, but the deal recently expired without an acquisition, leaving Acetylon to chart a new course. . —Option-to-buy deals are by definition no guarantee, and an agreement between Boston-based Acetylon Pharmaceuticals and Celgene is the latest example.

Google 40
article thumbnail

Interview with Zach James and Rich Raddon, MOVIECLIPS.COM

socalTECH

Studies show, if you don't, people will turn to piracy. I ended up taking a real job at Credit Suisse as an investment banker, where I spent time studying and finding hot new Internet companies that were in Silicon Valley at the time. We represented Google in the acquisition of YouTube. Rich Raddon: There are two things.

Startup 190
article thumbnail

7 Facts You Need to Know When Creating a Mobile App

Tech Zulu Event

Things you don’t read about in the Wall St Journal. The craziest part is that studies have started to show that users who download an app for free are likely to spend more than $0.99 Doesn’t it seem like its every person you see has an iPhone? I bet there is a lot that would surprise you about the mobile world.

Mobile 82